Analysis of metabolites - A new approach to bioequivalence studies of spironolactone formulations

International Journal of Clinical Pharmacology and Therapeutics

Volumn 35, Issue 8, 1997, Pages 334-340

  Vergin, H ^a   Mahr, G ^b   Metz, R ^a   Eichinger, A ^c   Nitsche, V ^c   Martens, H ^d  

^a Heumann Pharma GmbH   (Germany)

^b Biokinet GmbH   (Austria)

^c Mc Knight Laboratories GmbH   (Germany)

^d Heumann Pharma GmbH   (Germany)

Author keywords

7 thiomethylspirolactone; Bioequivalence; Canrenone; Metabolism; Spironolactone

Indexed keywords

7ALPHA THIOMETHYLSPIROLACTONE; CANRENONE; DRUG METABOLITE; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BIOTRANSFORMATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TRANSFORMATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ADULT; ALDOSTERONE ANTAGONISTS; ANALYSIS OF VARIANCE; CANRENONE; CROSS-OVER STUDIES; HUMANS; MALE; SPIRONOLACTONE; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 0030743813     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Blume H, Mutschier E 1989 Bioäquivalenz, Abschnitt Spironolactone. Govi, Eschborn
2. Blume HH, Scheidel B, Siewert M 1993 Application of single-dose vs multiple-dose studies. In: Midha KK, Blume HH (eds) Bio-International. Bioavailability, Bioequivalence and Pharmacokinetics. F.I.P. Paperback, Stuttgart, pp 171-188
3. Chen ML, Jackson AJ 1991 The role of metabolites in bioequivalence assessment. I. Linear pharmacokinetics without first-pass effect. Pharm Res 8: 25-32
4. Funder JW, Feldman D, Highland E, Edelman IS 1974 Molecular modifications of anti-aldosterone compounds: Effects on affinity of spirolactones for renal aldosterone receptors. Biochem Pharmacol 23: 1493-1501
5. Gardiner P. Schrode K, Quinlan D.Martin BK, Boreham DR, Rogers MS, Stubbs K. Smith M, Karim A 1989 Spironolactone metabolism: Steady state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 29: 342-347
6. Hauschke D, Steinijans VW, Diletti E 1990 A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28:. 72-78
7. Hettiarachchi J, Ramsay LE 1979 Spironolactone response related to plasma canrenone concentration. Br J Clin Pharmacol 7: 426P-427P
8. Jackson EK 1996 Diuretics. In: Gilman AG, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (eds) Goodman and Gilman's The Pharmacologic Basis of Therapeutics (9th edn). McGraw-Hill, New York, pp 706-709
9. Karim A. Hribar J, Doherty M. Aksamit W. Chappelow D, Brown E. Markos C, Chinn LJ, Liang D, Zagarella J 1977 Spironolactone: Diversity in metabolic pathways. Xenobiotica 7: 585-600
10. Karim A, Zagarella J, Hribar J, Dooley M 1976a Spironolactone. I. Disposition and metabolism. Clin Pharmacol Ther 19: 158-169
11. Karim A, Zagarella J. Hutsell TC, Chao A, Baltes BJ 1976b Spironolactone. II. Bioavailability. Clin Pharmacol Ther 19: 170-176
12. McInnes GT, Asbury MJ, Shelton JR.,Harrison IR, Ramsay LE, Venning GR, Clarke JM 1980 Activity of sulfur-containing intermediate metabolites of Spironolactone. Clin Pharmacol Ther 27: 363-369
13. Metz R, Muth P, Vergin H 1996 A new reversed phase HPLC method for determination of spironolactone and major metabolites in human plasma, 20th International Symposium on High Performance Liquid Phase Separations, June 16-21, 1996, San Francisco, USA, abstract No 261
14. Midha KK, Blume HH 1993 Conference Report Bio International 92. Session III: Importance of Metabolites in Assessment of Bioequivalence. Bio-International. Bioavailability, Bioequivalence and Pharmacokinetics. F.I.P. Paperback, Stuttgart, pp 147-208
15. Overdiek HWPM, Hermens WAJJ, Merkus FWHM 1985 New insights into the pharmacokinetics of spironolaclone. Clin Pharmacol Ther 38: 469-474
16. Overdiek HWPM. Merkus FWHM 1986 Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 40: 531-536
17. Sakauye C. Feldman D 1976 Agonist and antimineralocorticoid activities of spirolactones. Am J Physiol 231: 93-97
18. Tucker GT, Rostami A, Jackson PR 1993 Metabolites measurements in bioequivalence studies: Theoretical considerations. In: Midha KK, Blume HH (eds) Bio-International. Bioavailability, Bioequivalence and Pharmacokinetics. F.I.P. Paperback, Stuttgart, pp 163-170
19. Vergin H, NußU. Schwarzländer F. Strobel K. Weigand W. Hitzenberger G 1981 Bioverfügbarkeitsuntersuchungen zweier Spironolacton-Praparate. Arzneim-Forsch/Drug Res. 31 1498-1503